Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

• Published in: American journal of respiratory and critical care medicine Vol. 183; no. 8; pp. 1071 - 1079
• Main Authors: Chang, Tzu-Hua, Tsai, Meng-Feng, Su, Kang-Yi, Wu, Shang-Gin, Huang, Cheng-Po, Yu, Sung-Liang, Yu, Yung-Luen, Lan, Chou-Chin, Yang, Chih-Hsin, Lin, Shwu-Bin, Wu, Chin-Pyng, Shih, Jin-Yuan, Yang, Pan-Chyr
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 15.04.2011
• Subjects: Adenocarcinoma - drug therapy; Animals; Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Blotting, Western; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Cell Line, Tumor; Chemotherapy; Clinical medicine; Drug resistance; Drug Resistance, Neoplasm; Epidermal growth factor; Gene Knockout Techniques; Humans; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Medical research; Mice; Mutation; Neoplasms, Experimental - drug therapy; Polymerase chain reaction; Quinazolines - therapeutic use; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Snail Family Transcription Factors; Transcription Factors - genetics; Transcription Factors - physiology; Tumors

Non-small cell lung cancers carrying epidermal growth factor receptor (EGFR) mutations respond well to EGFR tyrosine kinase inhibitors (TKIs), but patients ultimately develop drug resistance and relapse. Although epithelial-mesenchymal transition (EMT) can predict resistance to EGFR TKIs, the molecu...